Roy Jakobs

Philips had been transformed over the previous decade from a diversified conglomerate (lighting, consumer electronics, healthcare) into a focused health technology company — only to be hit by the Respironics CPAP/ventilator recall, one of the largest medical device recalls in history. The Respironics crisis involved polyester-based polyurethane foam used for sound abatement in CPAP machines and ventilators degrading over time, potentially releasing particles and chemicals that patients could inhale. The recall affected approximately 5.5 million devices worldwide, resulted in over $5.5 billion in cumulative charges, a consent decree with the U.S. FDA restricting Respironics operations, and thousands of personal injury lawsuits. This crisis destroyed an enormous amount of shareholder value and reputational capital. Jakobs's leadership has focused on resolving the Respironics situation (completing device remediation, settling litigation, and complying with the consent decree), while simultaneously driving growth in Philips's core health technology businesses: diagnostic imaging (MRI, CT, ultrasound), patient monitoring, image-guided therapy, and connected care solutions. Key stock drivers include Respironics litigation resolution timeline and costs, FDA consent decree compliance progress, order growth in imaging and monitoring, and Jakobs's ability to restore customer and investor confidence in Philips as a reliable health technology partner.